Bavarian Nordic Reports Interim Data From Phase I/II Studies With Breast Cancer Vacci
Bavarian Nordic's cancer research unit, BN ImmunoTherapeutics, hascompleted an interim analysis of its first two clinical studies withMVA-BN(R)-HER2, a cancer vaccine immunotherapy for breast cancer patients. The first study, performed in the US, is evaluating MVA-BN(R)-HER2treatment following chemotherapy and Herceptin(R) treatment.
More... |
All times are GMT -7. The time now is 07:49 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021